Protein recombinant vaccine NVX-CoV2373 confers protection during Omicron dominant period in Italy

  • Post author:
  • Post category:uncategorized

The NVX-CoV2373 COVID-19 vaccine offers significant protection against symptomatic infections, but its effectiveness against SARS-CoV-2 declines within four months, according to a study in JAMA Network Open using Italian data. However, its protection against symptomatic COVID-19 seems to remain stable during this period.